Phase 2b non-comparative RCT in 122 adults with HIV on rifampicin-based TB treatment: twice-daily bictegravir-emtricitabine-tenofovir alafenamide achieved HIV-1 RNA <50 copies/mL at week 24 in 94% (75/80); 95% with dolutegravir.
RCTn = 122
Naidoo et al. Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial